The Fund’s general partner is CURR-ARC GP Limited, a joint venture company owned 80% by CURRENC and 20% by ARC Group. The investment focus of the Fund will be as follows: 1. Approximately 80% of the ...
Arteris’ FlexNoC network-on-chip (NoC) interconnect IP with the Functional Safety option provides Nextchip with optimal flexibility and superior ...
ClearSign Technologies Corporation (Nasdaq: CLIR) ("ClearSign" or the "Company") an emerging leader in industrial combustion and sensing technologies that support decarbonization, improve operational ...
IceCure Medical Ltd. ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results